Skip to main content

Werner J. Geldenhuys, B. Pharm, PhD

Associate Professor

Affiliations 

Pharmaceutical Sciences; Blanchette Rockefeller Neurosciences Institute 

Graduate Training

PhD in Medicinal Chemistry, North-West University, South Africa; MS in Pharmaceutical Chemistry, Potchefstroom University for CHE, South Africa

Fellowship

Postdoctoral Associate, Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech Health Sciences Center


Research Interests

My group focuses on the identification and development of novel therapeutics which can slow down the disease progression of Parkinson’s disease. Specifically, we focus on the mitochondrial protein mitoNEET. MitoNEET is a drug target for neurodegeneration. We use both small organic compounds and peptides drugs in our group. Additionally we use nanoparticles to deliver compounds and proteins to the brain to bypass the blood-brain barrier.


Research Topics

  • Parkinson's disease
  • Stroke
  • Alzheimer's disease
  • Drug discovery
  • Mitochondrial dysfunction
  • Neurodegeneration

Lab Personnel + Collaborators


Recent Publications

[2017]

[2016]

[2015]

  • Geldenhuys WJ, Guseman TL, Pienaar IS, Dluzen DE, Young JW.  A novelbiomechanical analysis of gait changes in the MPTP mouse model of Parkinson's disease  PeerJ. 2015 Aug 11;3:e1175. doi: 10.7717/peerj.1175. eCollection 2015. PubMed PMID: 26339553; PubMed Central PMCID: PMC4558067.
  • Geldenhuys WJ, Mohammad AS, Adkins CE, Lockman PR.  Molecular determinants of blood-brain barrier permeationTher Deliv. 2015;6(8):961-71. doi: 10.4155/tde.15.32. Epub 2015 Aug 25. PubMed PMID: 26305616; PubMed Central PMCID: PMC4675962.
  • Geldenhuys WJ, Darvesh AS.  Pharmacotherapy of Alzheimer's disease: current and future trendsExpert Rev Neurother. 2015 Jan;15(1):3-5. doi: 10.1586/14737175.2015.990884. Epub 2014 Dec 8. Review. PubMed PMID: 25481975.
  • Geldenhuys WJ, Kochi A, Lin L, Sutariya V, Dluzen DE, Van der Schyf CJ, Lim MH.  Methyl Yellow: A Potential Drug Scaffold for Parkinson's Disease. Chembiochem. 2014 Jul 8. doi: 10.1002/cbic.201300770. [Epub ahead of print] PubMed PMID: 25045125.
  • Geldenhuys WJ, Abdelmagid SM, Gallegos PJ, Safadi FF.  Parkinson's disease biomarker: a patent evaluation of WO2013153386Expert Opin Ther Pat. 2014 Aug;24(8):947-51. doi: 10.1517/13543776.2014.931375. Epub 2014 Jun 25. PubMed PMID: 24962176.
  • Kumar V, Weng YC,  Geldenhuys WJ, Wang D, Han X, Messing RO, Chou WH. Generation and characterization of ATP analog-specific protein kinase CδJ Biol Chem. 2015 Jan 23;290(4):1936-51. doi: 10.1074/jbc.M114.598698. Epub 2014 Dec 10.PubMed PMID: 25505183; PubMed Central PMCID: PMC4303651.

More publications: https://www.ncbi.nlm.nih.gov/pubmed/?term=geldenhuys+w